Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheime
RecruitingNCT05509387Phase: NAStarted 2022-09-01
Summary
There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with transcranial direct c
Eligibility
Sex
ALL
Min Age
50 Years
Max Age
90 Years
Locations
Baycrest Health SciencesToronto, Ontario, Canada
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT05509387